The present invention relates to an oral thin film comprising at least one polymer and at least one pharmaceutically active ingredient, the oral thin film being substantially U-shaped, and to the use of said oral thin film as a medicament, especially for sub-lingual administration.

The present invention relates to a water resistant wound cover with high comfort and good air permeability. In particular, the present invention relates to an aqueous wound healing formulation comprising a water-soluble or a water-dispersible polymeric material that does not sting when applied to a minor injury to the skin.

Disclosed herein are topical formulations comprising about 0.001 to about 3 wt % detomidine or a salt thereof; and, a carrier that is suitable for topical administration to a subjects skin, wherein the carrier comprises hydrophilic and hydrophobic phase members in specified ratios, and wherein the detomidine is fully dissolved and chemically stable in the hydrophilic phase member. The topical formulations may be provided in the form of emulsions, creams, ointments, gels, spray patches, dispersions, and other specified forms. Also provided are methods for providing prolonged, non-systemic treatment for pain in a subject in need thereof comprising topically administering to the subject the presently disclosed topical formulations.

The present invention provides a sustained drug delivery system for the treatment of age-related macular degeneration (AMD), comprising corticosteroid encapsulated nanoparticles incorporated into a thermoreversible hydrogel. The corticosteroid may be triamcinolone acetate (TA), dexamethasone, or loteprednol etabonate (LE). The proposed drug delivery system is nontoxic to ARPE-19 (retinal pigment epithelium) cells and significantly reduces VEGF (vascular endothelial growth factor) expression as compared to solutions of the coticosteroids. The present invention provides sustained delivery of the corticosteroid to the posterior segment of the eye, reducing the frequency of intraocular injections necessary to maintain therapeutic concentrations.

The present invention examines the interaction between an angiopoietin-1 mimetic peptide, QHREDGS (glutamine-histidine-arginine-glutamic acid-aspartic acid-glycine-serine (SEQ ID NO: 1)) immobilized to a collagen-chitosan hydrogel, and murine bone marrow derived macrophages. When macrophages were cultured in the presence of the peptide conjugated to a hydrogel, both pro-inflammatory and anti-inflammatory cytokines were produced, in contrast to the application of soluble peptide which elicited minimal cytokine secretion. This indicates a unique macrophage polarization with covalently immobilized peptide hydrogels, which can be beneficial in the context of the wound microenvironment.

An oxygen-releasing biomaterial, articles and methods, and more particularly an oxygen-releasing biomaterial with sustained oxygen-releasing properties of four to five weeks, which is suitable for tissue engineering scaffolds, is disclosed. The biomaterial contains a hydrogel with a plurality of microparticles suspended in the hydrogel. The microparticles contain an oxygen carrier that is encapsulated in a biocompatible hydrophobic material, where the release of oxygen from the oxygen carrier is sustained over a four to five week period. The biomaterial has application in tissue engineering, osteogenesis, burn and wound treatment, and treatment of cardiac conditions, and has further antimicrobial properties.

The present invention relates to a method for treating skin, comprising the following step A) and then step B): A) physically or chemically treating an epidermis of the skin; and B) forming a film containing a fiber deposit on the skin which has been subjected to the step A). When the above step B) is applied to the skin after the conventional step A), skin conditions such as inflammation, redness, and swelling caused by the step A) are alleviated, these conditions disappear more quickly, and the quality of life (QOL) of persons who have undergone the cosmetic or dermatological treatment is significantly improved.

It is disclosed a pharmaceutical and/or phytosanitary composition comprising an aqueous extract of Chelidonium majus root and an acceptable pharmaceutical or phytosanitary excipient for the prevention or treatment of nail infections. The composition may further comprise an aqueous extract of Thuja occidentalis leaf; and from about 1 to 5% of at least one natural phenolic compound. The composition is efficient in the treatment of plant infection (mildew fungus, blight fungus, etc); the treatment of intumescence of a plant; the treatment of potatoes (powdery or common scab, Rhizoctonia, etc), and also allows a higher crop yield: without the use of a chemical fungicide. The composition also allows rapid treatment of fungus infection of nails.

The present invention relates to nitric oxide (NO)-releasing nail coating compositions, NO-releasing coatings, and methods of using the same, for example, to treat fungal infections of a nail. It is noted that aspects described with respect to one embodiment may be incorporated in different embodiments although not specifically described relative thereto. Provided according to embodiments of the invention are nitric oxide (NO)-releasing nail coating compositions and/or coatings.

Provided is a composition for forming a coating film directly on the skin by an electrostatic spray, the composition being capable of forming a coating film having excellent skin compatibility, adhesion, and scratch resistance, having a good feel, and being easy to peel. A composition for forming a coating film, for forming a coating film composed of fibers directly on the skin by an electrostatic spray, the composition comprising the following Components (a), (b), (c), and (d): (a) a polymer having a coating film forming ability (b) one or more volatile substances selected from the group consisting of an alcohol and a ketone (c) a plasticizer (d) a feel modifier other than Component (c).